Quanterix Corporation

NASDAQGM:QTRX

Yhdysvallat / Terveydenhuolto / Biotieteiden työkalut ja palvelut

Yhteenveto

Osingot

10 vuoden rahoitusvälineet

Osakekurssi

7,22 USD


Key Metrics	Latest
Total Revenue	137,4 M
Adjusted EBITDA	-46,153 M
EBITDA Margin	-33,6%
Net Profit Margin	-28,0%
Total Assets	406,5 M
Total Debt	37,371 M

10Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending										Latest
(in millions)	Dec-15	Dec-16	Dec-17	Dec-18	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	12 Months

Revenue	12	18	23	38	57	86	111	106	122	137	137
% Growth		44.4%	30.1%	64.5%	50.8%	52.2%	28.0%	-4.6%	16.0%	12.3%

Adjusted EBITDA	(14)	(21)	(26)	(30)	(36)	(27)	(52)	(68)	(35)	(46)	(46)
% Margin	-115.7%	-120.9%	-111.6%	-80.0%	-63.6%	-30.7%	-46.7%	-64.3%	-28.3%	-33.6%	-33.6%

Adjusted EBIT	(15)	(22)	(26)	(31)	(39)	(31)	(57)	(73)	(41)	(53)	(53)
% Margin	-119.2%	-123.5%	-113.7%	-83.6%	-68.9%	-35.7%	-51.1%	-69.5%	-33.5%	-38.3%	-38.3%

Adjusted Net Income	(16)	(23)	(27)	(31)	(39)	(31)	(57)	(77)	(27)	(39)	(39)
% Margin	-130.9%	-131.8%	-118.1%	-83.6%	-68.6%	-35.9%	-51.4%	-73.2%	-21.8%	-28.0%	-28.0%

Adjusted Basic EPS	(8.79)	(10.81)	(7.19)	(1.43)	(1.55)	(1.05)	(1.58)	(2.09)	(0.71)	(1.00)	(1.00)

Tukevat laskelmat

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
											Press Release
USD	Fiscal Year Ending										Latest
(in millions)	Dec-15	Dec-16	Dec-17	Dec-18	Dec-19	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	Dec-24
	FY - 9	FY - 8	FY - 7	FY - 6	FY - 5	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM

Revenue	12	18	23	38	57	86	111	106	122	137	137
% Growth	NA	44.4%	30.1%	64.5%	50.8%	52.2%	28.0%	-4.6%	16.0%	12.3%

Cost of Revenue	(6)	(10)	(13)	(20)	(29)	(37)	(46)	(60)	(48)	(54)	(54)
Gross Profit	6	8	10	18	27	49	65	45	74	83	83
% Revenue	46.9%	44.1%	43.7%	47.7%	48.4%	56.6%	58.6%	43.0%	60.7%	60.5%	60.5%

Research and Development	(10)	(17)	(16)	(16)	(16)	(20)	(28)	(27)	(26)	(31)	(31)
Selling and Marketing	0	0	0	0	0	0	(1)	(0)	(0)	0	0
General and Admin	(10)	(12)	(20)	(34)	(50)	(60)	(92)	(92)	(89)	(105)	(105)
Other Inc / (Exp)	(0)	(0)	(0)	(0)	(3)	(1)	1	(31)	(3)	(0)	(0)
Total Operating Exp	(21)	(30)	(36)	(50)	(69)	(81)	(120)	(150)	(118)	(136)	(136)

Operating Income	(15)	(22)	(26)	(32)	(42)	(32)	(55)	(105)	(43)	(53)	(53)
% Revenue	-122.4%	-124.4%	-114.0%	-83.9%	-73.3%	-36.6%	-49.9%	-99.1%	-35.5%	-38.4%	-38.4%

Interest Expense	(1)	(1)	(1)	0	1	(0)	(0)	5	16	15	15
Pre-tax Income	(16)	(23)	(27)	(32)	(41)	(32)	(56)	(99)	(28)	(38)	(38)
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0	0	0	0
Provision for Taxes	0	0	0	(0)	0	0	0	(0)	(1)	(0)	(0)
Net Income to Company	(16)	(23)	(27)	(32)	(41)	(32)	(56)	(100)	(28)	(39)	(39)
% Margin	-130.9%	-131.8%	-118.1%	-83.8%	-71.9%	-36.5%	-50.2%	-94.4%	-23.2%	-28.0%	-28.0%

Minority Interest in Earnings	0	0	0	0	0	0	0	0	0	0	0
Net Income to Stockholders	(16)	(23)	(27)	(32)	(41)	(32)	(56)	(100)	(28)	(39)	(39)

Preferred Dividends	0	(0)	(0)	0	0	0	0	0	0	0	0
Other Adj.	(4)	(4)	(4)	0	0	0	0	0	0	0	0

Net Income to Common	(20)	(28)	(31)	(32)	(41)	(32)	(56)	(100)	(28)	(39)	(39)
% Margin	-166.7%	-157.1%	-136.3%	-83.8%	-71.9%	-36.5%	-50.2%	-94.4%	-23.2%	-28.0%	-28.0%

As Reported
Basic EPS (Continuing Ops)	(11.19)	(12.89)	(8.30)	(1.43)	(1.63)	(1.07)	(1.54)	(2.69)	(0.75)	(1.00)	(1.00)
Diluted EPS (Continuing Ops)	(11.19)	(12.89)	(8.30)	(1.43)	(1.63)	(1.07)	(1.54)	(2.69)	(0.75)	(1.00)	(1.00)

WA Basic Shares Out.	1.81	2.14	3.76	21.99	25.09	29.59	36.00	36.99	37.59	38.37	38.37
WA Diluted Shares Out.	1.81	2.14	3.76	21.99	25.09	29.59	36.00	36.99	37.59	38.37	38.37

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	(16)	(23)	(27)	(32)	(41)	(32)	(56)	(99)	(28)	(38)	(38)
Addback: Net Interest Expense	1	1	1	(0)	(1)	0	0	(5)	(16)	(15)	(15)
Addback: Other Non Operating Expenses, Total	0	0	0	0	0	0	0	1	0	0	0
Addback: Depreciation & Amortization	0	0	0	1	3	4	5	5	6	6	6
Addback: Restructuring Charges	0	0	0	0	0	0	0	31	4	0	0
Addback: Merger / Acquisition Expenses	0	0	0	0	3	1	0	0	0	0	0
Addback: Goodwill Impairment	0	0	0	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	0	0	0	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Assets	0	0	0	0	0	0	0	0	0	0	0
Addback: Asset Writedown	0	0	0	0	0	0	0	0	1	0	0
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	0	0	0	0	0	0	(2)	(1)	(3)	0	0
Adjusted EBITDA	(14)	(21)	(26)	(30)	(36)	(27)	(52)	(68)	(35)	(46)	(46)
% Margin	-115.7%	-120.9%	-111.6%	-80.0%	-63.6%	-30.7%	-46.7%	-64.3%	-28.3%	-33.6%	-33.6%

Adjusted EBIT	(15)	(22)	(26)	(31)	(39)	(31)	(57)	(73)	(41)	(53)	(53)
% Margin	-119.2%	-123.5%	-113.7%	-83.6%	-68.9%	-35.7%	-51.1%	-69.5%	-33.5%	-38.3%	-38.3%

Adjusted Net Income Reconciliation
Net Income to Company	(16)	(23)	(27)	(32)	(41)	(32)	(56)	(100)	(28)	(39)	(39)
Addback: Unusual Items	0	0	0	0	3	1	(2)	30	2	0	0
Less: Tax Benefit of Unusual Items (26%)	0	0	0	(0)	(1)	(0)	0	(8)	(1)	0	0
Adjusted Net Income	(16)	(23)	(27)	(31)	(39)	(31)	(57)	(77)	(27)	(39)	(39)
% Margin	-130.9%	-131.8%	-118.1%	-83.6%	-68.6%	-35.9%	-51.4%	-73.2%	-21.8%	-28.0%	-28.0%

Kaikki oikeudet pidätetään. Käyttöehdot

Latausvirhe

Quanterix Corporation

NASDAQGM:QTRX

Yhdysvallat / Terveydenhuolto / Biotieteiden työkalut ja palvelut

10 vuoden rahoitusvälineet